Catalyst Wire Dossier Catalyst Wire Dossier

ARX-F02 (Sufentanil NanoTab)

sufentanil · Talphera, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARX-F02 (Sufentanil NanoTab), covering 2015-01-01 to 2015-01-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study for the Evaluation of the Safety, Tolerability, and Efficacy of ARX-F02 (Sufentanil NanoTab) Compared to Placebo in the Treatment of Cancer Breakthrough Pain [Phase 2]

See pricing